Corcept Therapeutics Presents Phase 3 GRACE Trial Results for Relacorilant in Cushing’s Syndrome

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company specializing in developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, has announced the upcoming presentation of the results from its Phase 3 trial of relacorilant, a selective cortisol modulator, in patients with Cushing’s syndrome. The findings from the GRACE study will be presented at both the Endocrine Society (ENDO) annual meeting in Boston on June 3 and the Heart in Diabetes (HiD) conference in Philadelphia on June 7.

ENDO 2024 Presentation Details:
- Event: ENDO 2024, Boston Convention & Exhibition Center
- Session: P108 - Late-Breaking Poster Presentations: Day 3
- Presentation Title: Open-label Results From GRACE, A Phase 3 Double-blind, Randomized-withdrawal Study Of The Selective Glucocorticoid Receptor Modulator Relacorilant For The Treatment Of Endogenous Hypercortisolism (Cushing Syndrome)
- Date & Time: Monday, June 3, 2024, 12:00-1:30 pm ET
- Presenter: Rosario Pivonello, MD, PhD, Principal Investigator of the GRACE study and Professor of Endocrinology at Università Federico II di Napoli, Italy

Heart in Diabetes Conference Presentation Details:
- Event: 8th Heart in Diabetes Conference, Hilton Penn’s Landing
- Session: Hypercortisolism Implication to Cardiorenal & Metabolic Diseases
- First Presentation Title: Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond
- Date & Time: Friday, June 7, 2024, 3:50-4:00 pm ET
- Presenter: Ralph DeFronzo, MD, Chief of the Diabetes Division and Professor of Medicine at UT Health San Antonio
- Second Presentation Title: Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
- Date & Time: Friday, June 7, 2024, 4:00-4:20 pm ET
- Presenter: Rosario Pivonello, MD, PhD

These presentations will be accessible on Corcept’s official website following the events.

About Relacorilant:
Relacorilant is a selective cortisol modulator that specifically binds to the glucocorticoid receptor, avoiding interactions with other hormone receptors. Corcept is exploring relacorilant's potential in treating various severe conditions, including ovarian, adrenal, and prostate cancer alongside Cushing’s syndrome. The drug is protected by several patents and holds orphan drug designation in the United States and the European Union for treating Cushing’s syndrome.

About Corcept Therapeutics:
Established over 25 years ago, Corcept Therapeutics has focused on cortisol modulation to address a range of serious disorders. The company has developed over 1,000 proprietary selective cortisol modulators and is conducting advanced clinical trials for hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS), and liver disease. Corcept's first approved medication, Korlym®, received FDA approval in February 2012 for Cushing’s syndrome treatment. The company is headquartered in Menlo Park, California.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!